A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. [electronic resource]
Producer: 20080416Description: 746-51 p. digitalISSN:- 1569-8041
- Administration, Oral
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Hormonal -- therapeutic use
- Benzenesulfonates -- administration & dosage
- Biomarkers, Tumor -- analysis
- Canada
- Cell Proliferation -- drug effects
- Disease Progression
- Disease-Free Survival
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Lymphatic Metastasis
- Male
- Middle Aged
- Neoplasms, Hormone-Dependent -- blood supply
- Neovascularization, Pathologic -- drug therapy
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- blood supply
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Sorafenib
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.